This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
April 06, 2020
GenSight Biologics Provides Update on Operations in the Context of COVID-19
April 06, 2020
Aprea Therapeutics Launches New Corporate Website – www.aprea.com
April 03, 2020
BONESUPPORT HOLDING AB (publ) publishes 2019 Annual Report and comments on effects of COVID-19
April 02, 2020
Oncopeptides strengthens its corporate communications function by appointing Rolf Gulliksen as Global Head of Corporate Communications
April 01, 2020
Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021
March 31, 2020
Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
March 30, 2020
Vicore submits clinical trial application for phase II trial with C21 in IPF 2020-03-30
March 27, 2020
Nordic Nanovector ASA publishes 2019 Annual Report
March 26, 2020
Orexo publishes the Annual Report for 2019
March 26, 2020
Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study